110例老年食管癌调强放疗疗效及预后分析

doi:10.13491/j.issn.1004-714x.2018.04.011

中国辐射卫生

2018, Vol. 27

Issue (4): 331-335 DOI: 10.13491/j.issn.1004-714x.2018.04.011

本期目录 | 过刊浏览 | 高级检索

110例老年食管癌调强放疗疗效及预后分析

黄勇, 毕金玲

安徽省合肥市第二人民医院广德路院区肿瘤科, 安徽合肥 230011

The efficacy and prognosis of intensity-modulated radiotherapy for 110 cases of elderly esophageal cancer

HUANG Yong, BI Jinling

Department of Oncology, Guangde Road, Hefei Second People's Hospital, Hefei 230011 China

摘要
图/表
参考文献
相关文章 (3)

全文: PDF (4269 KB) HTML ( )
输出: BibTeX | EndNote (RIS)

摘要目的探讨老年食管癌患者调强放疗（intensity modulated radiation therapy，IMRT）疗效及相关预后因素。方法回顾性分析2014年1月-2017年3月安徽省合肥市第二人民医院肿瘤科符合条件的110例初治接受IMRT的年龄65岁以上的食管癌患者的临床疗效及相关预后因素。结果 110例患者，中位年龄77岁；中位生存时间为19.5个月，1、2、3和5年生存率分别为67%、49%、28%和9%；全组I、Ⅱ、Ⅲ级急性放射性肺炎的发生率分别为5.3%、0.9%、0.4%，I、Ⅱ、Ⅲ级急性放射性食管炎的发生率分别为36.2%、4.8%、2.1%，I、Ⅱ、Ⅲ级骨髓抑制的发生率分别为29.6%、13.7%、2.7%，I、Ⅱ、Ⅲ级消化道反应的发生率分别为13.1%、3.4%、0.1%，无IV级及以上放射性损伤。COX多因素分析显示，病变部位、GTV及治疗方法与患者的预后明显相关。结论 IMRT是老年食管癌患者安全有效的治疗方式之一。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄勇
	毕金玲

关键词 ：老年食管癌, IMRT, 预后

收稿日期: 2018-03-04

PACS:

R815.6

基金资助:合肥市卫生计生委2017年应用医学研究项目（hwk2017zd010）

作者简介: 黄勇(1967-),男,安徽合肥人,副主任医师,从事肿瘤放化疗工作。E-mail:hy670716@163.com

引用本文:

黄勇, 毕金玲. 110例老年食管癌调强放疗疗效及预后分析[J]. 中国辐射卫生, 2018, 27(4): 331-335.
HUANG Yong, BI Jinling. The efficacy and prognosis of intensity-modulated radiotherapy for 110 cases of elderly esophageal cancer. , 2018, 27(4): 331-335.

链接本文:

http://www.zgfsws.com/CN/10.13491/j.issn.1004-714x.2018.04.011 或 http://www.zgfsws.com/CN/Y2018/V27/I4/331

[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015.CA Cancer[J]. Clin, 2016,66:115-132.
[2] Ji Y, Qiu G, Sheng L, et al. A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer[J]. Thorac Dis, 2016, 8:451-458.
[3] Won E, Ilson DH. Management of localized esophageal cancer in the older patient[J]. Oncologist, 2014, 19:367-374.
[4] In-Seob Lee, Ji-Yong Ahn, Jeong-Hwan Yook, et al.Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma[J].World J Surg Oncol, 2017,15(1):28.
[5] Yun Chen, Zhengfei Zhu, Weixin Zhao, et al. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai1 trial protocol[J].Radiat Oncol, 2018, 13(1):33.
[6] Zeng Y, Liang W, Liu J, et al. Esophageal cancer in elderly patients:a population-based study[J].Thorac Dis, 2018,10(1):448-457.
[7] Ohira M, Kubo N, Yamashita Y, et al.Impact of Chemoradiation-induced Myelosuppression on Prognosis of Patients with LocallyAdvanced Esophageal Cancer After Chemoradiotherapy Followed by Esophagectomy[J].Anticancer Res, 2015, 35(9):4889-4895.
[8] Tougeron D, Hamidou H, Scotté M, et al. Esophageal cancer in the elderly:an analysis of the factors associated with treatment decisions and outcomes[J].BMC Cancer, 2010, 10:510.
[9] Kuwai T, Yamaguchi T, Imagawa H, et al.Endoscopic submucosal dissection for early esophageal neoplasms using the stag beetle knife[J].World J Gastroenterol, 2018, 24(15):1632-1640.
[10] 孔洁,李晓宁,韩春,等.792例食管癌三维技术放疗的疗效分析[J].中华放射肿瘤学杂志,2012,21(5):421-422.
[11] 王澜,孔洁,韩春,等.781例不同部位食管癌三维放疗预后分析[J].中华放射肿瘤学杂志,2013,22(1):18-21.
[12] Morita M, Egashira A, Nakaji YU, et al. Treatment of Squamous Cell Carcinoma of the Esophagus Synchronously Associated with Head and Neck Cancer[J].In Vivo, 2017,31(5):909-916.
[13] National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN Guidelines).Esophageal and Esophagogastric Junction Cancers 2015. NCCN.org.
[14] Pallari E, Fox AW, Lewison G. Differential research impact in cancer practice guidelines' evidence base:lessons from ESMO,NICE and SIGN[J].ESMO Open, 2018,3(1):e000258.
[15] 万钧,韩春,刘惠明.食管癌的放射治疗[M].北京:原子能出版社,2006:101-111.
[16] 潘丁龙,李建成,杨燕,等.210例中晚期食管癌放化疗的预后因素分析[J].临床肿瘤学杂志,2015,20(2):140-144.
[17] Wu Z, Su Y, Zeng RF, et al. Prognostic value of tumor volume for patients with nasopharyngeal carcinoma treated with concurrent chemotherapy and intensity-modulated radiotherapy[J].Cancer Res Clin Oncol, 2014,140(1):69-76.
[18] Setakornnukul J, Thephamongkhol K.Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrentchemoradiotherapy followed by adjuvant chemotherapy in locally advancednasopharyngeal carcinoma[J].BMC Cancer, 2018,18(1):329.
[19] endenhall WM, Morris CG, Amdur Pd, et a1.Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma ofthe head and neck[J].Head Neck,2003,25(7):535-542.
[20] Fujii S, Iwata N, Inoue C, et a1.Volume Measurement by Diffusion-Weighted Imaging in Cervical Cancer[J].Yonago Acta Med, 2017,60(2):113-118.
[21] Reymen B, van Loon J, van Baardwijk A,et a1.Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I toⅢsmall cell lung cancer[J].Int J Radiat Oncol Bid Phys, 2013,85(5):1319-1324.
[22] Chen Y, Zhang Z, Jiang G,et a1.Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patientstreated with definitive radiotherapy[J].Thorac Dis, 2016,8(6):1155-1161.
[23] 万欣,乔学英,王雅棣,等.13l例食管鳞癌三维适形放疗预后因素分析[J].中华放射肿瘤学杂志,201l,20(3):202-204.
[24] Vlacich G, Samson PP, Perkins SM, et al.Treatment utilization and outcomes in elderly patients with locally advanced esophagealcarcinoma:a review of the National Cancer Database[J].Cancer Med, 2017,6(12):2886-2896.
[25] Smith GL, Smith BD,Buchholz TA,et al.Patterns of care and locoregional treatment outcomes in older esophageal cancer patients:The SEER-Medicare Cohort[J]. Int J Radiat Oncol Biol Phys, 2009, 74(2):482-489.
[26] Lu X,Wu H,Wang J,et al.Factors affecting long-term survival in elderly patients undergoing radiotherapy for esophageal carcinoma[J].Mol Clin Oncol, 2014,2:571-574.
[27] Xu HY, Du ZD, Zhou L,et al. Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma[J].Oncol Lett, 2014,7:260-266.
[28] Lv S, Fang M, Yang J, et al.Long-term results of definitive concurrent chemoradiotherapy using S-1 in the treatment of geriatric patients with esophageal cancer[J].Onco Targets Ther, 2016,9:5389-5397.